Boston Scientific Announces FDA Approval of Harmony(TM)
HiResolution(R)
September 2006
Editor: We've been expecting the announcement of FDA approval of the
Harmony system for some time, so this is not unexpected. What is unexpected,
at least to me, is the fact that "Advanced Bionics" doesn't show up anywhere
in this press release. For those who don't know, Advanced Bionics has
produced cochlear implants for years and was recently bought by Boston
Scientific.
~~~~~~~~~~~~~~~~~
NATICK, Mass., Sept. 27 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX - News) today announced the approval of its new
Harmony(TM) HiResolution(r) Bionic Ear System (Harmony System) by the U.S.
Food and Drug Administration (FDA). Developed by the Company's
Neuromodulation Group, the Harmony System delivers 120 spectral bands, 5 -
10 times more than competing systems, helping to significantly increase
hearing potential and quality of life for the severe-to-profoundly deaf. The
Harmony System represents the next generation of cochlear implant
technology," said Jeff Greiner, President of Boston Scientific's
Neuromodulation Group. "We have brought together unprecedented advancements
in science, design and functionality for the user -- furthering our
commitment to restoring hearing and improving quality of life for those
living with hearing loss due to permanent inner ear or auditory nerve
damage."
Designed to enhance music appreciation and improve hearing in a variety
of difficult listening environments, the Harmony System couples
revolutionary internal sound processing (with the optional HiRes Fidelity(TM)
120) with the new Harmony behind-the-ear (BTE) external sound processor.
Together, the two key components of the Harmony System are designed to
provide significantly enhanced spectral resolution compared to conventional
systems for a more natural representation of sound to help improve patient
performance.
"With the new Harmony System, we are able to actively steer electrical
currents with a high degree of accuracy, increasing the number of spectral
bands from 16 to 120," said Greiner. "We are attempting to guide precise
pitch information into the cochlea by taking advantage of surviving neural
populations to help increase the user's ability to hear in noisy
environments and to better appreciate the intricate sounds of music."
Cochlear implant users can access soft whispers and loud sounds without
adjusting dials or controls with Harmony's CD-quality processing and
sophisticated dual-loop automatic gain control, helping users better
appreciate music, hear in noisy environments, use the telephone, and hear
sounds that are loud and soft.
In addition to the FDA approval, the Harmony HiResolution Bionic Ear
System recently received approval from Health Canada and the CE mark in
Europe.
According to clinical evaluation results, approximately 80 percent of the
subjects reported a strong preference for the Harmony sound processor with
HiRes Fidelity 120, most noting that they had improved clarity of speech
and/or that environmental sounds were clearer and easier to distinguish .
The HiResolution Bionic Ear System with optional HiRes Fidelity 120 is
approved in the U.S. for adults only at this time and for all patients in
Canada and Europe. The product is expected to be available in early 2007.
People interested in bionic ear technology to restore hearing should
speak to their physicians and visit http://www.bionicear.com or call
800-678-2575 for more information.
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. The Neuromodulation Group is a global leader in the
development of implantable, high-technology neurostimulation devices that
include treatments for deafness and chronic pain. For more information,
please visit http://www.bostonscientific.com or http://www.bionicear.com.
This press release contains forward-looking statements. Boston Scientific
wishes to caution the reader of this press release that actual results may
differ from those discussed in the forward-looking statements and may be
adversely affected by, among other things, risks associated with new product
development and commercialization, clinical trials, intellectual property,
regulatory approvals, competitive offerings, integration of acquired
companies, Boston Scientific's overall business strategy, and other factors
described in Boston Scientific's filings with the Securities and Exchange
Commission.